As of 2026-06-12, the Intrinsic Value of SynAct Pharma AB (SYNACT.ST) is -8.72 SEK. This SYNACT.ST valuation is based on the model Peter Lynch Fair Value. With the current market price of 13.80 SEK, the upside of SynAct Pharma AB is -163.18%.
Based on its market price of 13.80 SEK and our intrinsic valuation, SynAct Pharma AB (SYNACT.ST) is overvalued by 163.18%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -8.72 - -8.72 | -8.72 | -163.18% |
| P/E | (59.68) - (57.20) | (57.02) | -513.2% |
| DDM - Stable | (24.15) - (141.98) | (83.06) | -701.9% |
| DDM - Multi | (22.83) - (104.66) | (37.52) | -371.9% |
| Market Cap (mil) | 883.37 |
| Beta | 0.67 |
| Outstanding shares (mil) | 64.01 |
| Enterprise Value (mil) | 818.66 |
| Market risk premium | 5.10% |
| Cost of Equity | 7.08% |
| Cost of Debt | 5.00% |
| WACC | 7.08% |